What Is MT1?
MT1 (Melanotan-1, also known as afamelanotide) is a synthetic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). It is studied for its effects on skin pigmentation, photoprotection, and melanin production. MT1 works by stimulating pathways involved in natural pigment formation rather than acting as a hormone related to appetite or metabolism.
MT1 is not a weight-loss medication. Its primary research focus involves skin response to ultraviolet (UV) exposure and pigmentation support.
How Does MT1 Work?
MT1 interacts with melanocortin receptors that regulate pigment production:
- Melanocortin-1 receptors (MC1R) — Stimulate melanin production within the skin.
- Melanin signaling — Encourages increased pigment formation, which may contribute to tanning and UV protection.
- Cellular photoprotection pathways — Studied for potential support against UV-related skin stress.
Rather than directly darkening the skin like a dye, MT1 works by enhancing the body’s natural melanin response.
Potential Benefits?
- Support for gradual skin pigmentation
- Photoprotection and UV tolerance
- More even tanning response in some individuals
- Skin health in specific medical conditions
Side Effects and Safety Considerations?
Reported effects may include:
- Nausea or flushing
- Increased freckling or darkening of existing moles
- Fatigue or mild headache
- Injection-site irritation with subcutaneous use
Because MT1 influences pigment pathways, skin changes should be monitored carefully. Long-term safety considerations may vary depending on individual response and exposure to sunlight.
Recommended Usage Information?
Estimated half-life is approximately 30–60 minutes, although biological effects may last longer due to receptor activation.
Why it matters:
- MT1 does not remain in the bloodstream for days like long-acting metabolic peptides
- Often discussed with more frequent administration
- Pigmentation effects build gradually over time rather than immediately
Steady state concepts used for long-acting weekly medications do not apply in the same way to MT1. Instead, consistent administration over time may allow melanin levels and visible effects to develop progressively.
Start on a daily dose of 0.2mg, and adjust accordingly.
Gradual increases are typically preferred over rapid escalation to help manage tolerability. Higher amounts are not always necessary — maintaining a consistent approach once desired pigmentation is achieved may help reduce unwanted side effects.
Our pens have an adjustable dosage of 0.2–2mg, and have a shelf life of 12–18 months.